Running studies

ESCAPE

Prospective Clinical Trial

Efficiency in management of organ dysfunction associated with infection by the novel SARS-CoV-2 virus through a personalized immunotherapy approach.

SAVE

Clinical Trial

suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL

ACHIEVE

Clinical Trial

ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 INFECTION EARLY: The ACHIEVE open-label non-randomized Cninical Trial

ACTIVATE II

Clinical Trial

A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL

SAVE-MORE

Clinical Trial

suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL